Samantha Koons
4 Papers
Samantha Koons is an academic researcher. The author has contributed to research in topics: Psoriatic arthritis & Psoriasis. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.
Joel M. Gelfand,April Armstrong,Stacie Bell,George L. Anesi,Andrew Blauvelt,Cassandra Calabrese,Erica D. Dommasch,Steve R. Feldman,Dafna D. Gladman,Dafna D. Gladman,Leon H Kircik,Leon H Kircik,Mark Lebwohl,Vincent Lo Re,George R. Martin,Joseph F. Merola,Jose U. Scher,Sergio Schwartzman,James R. Treat,Abby S. Van Voorhees,Christoph T. Ellebrecht,Justine Fenner,Anthony Ocon,Maha N. Syed,Erica J. Weinstein,Jessica Smith,George Gondo,Sue Heydon,Samantha Koons,Christopher T. Ritchlin +29 more
TL;DR: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 and what they should do if they develop CO VID-19.
50
Viewing Psoriasis as a Systemic Disease for Better Health Outcomes
George Gondo,Samantha Koons,Claire Metcalf,Stacie Bell,Nehal N. Mehta +4 more
- 01 Jun 2021
TL;DR: An infographic condensing these long-awaited psoriatic disease guidelines offers providers a tool for easy comprehension and prioritization of care and a resource for discussions with patients, a key highlight of the guidelines.
3
Non-Medical Switching Impact on Patients and Providers – Psoriatic Disease Community Taking a Stand
April W. Armstrong,Mark Lebwohl,Joseph F. Merola,Samantha Koons,R. Fried,J. Hawkes,John Koo,Richard G. Langley,George Martin,Soumya M. Reddy,Sergio Schwartzman,Evan L. Siegel,A.S. Van Voorhees,E. Wallace,Jeffrey M Weinberg,L. Howard,Stacie Bell +16 more
- 08 Jun 2021
TL;DR: Non-medical switching (NMS) occurs when a payer mandates that patients switch therapies, either within or across therapeutic classes, for non-medical reasons, which can increase the disease burden and present safety risks for patients.
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments.
Joel M. Gelfand,April Armstrong,Stacie Bell,George L. Anesi,Andrew Blauvelt,Cassandra Calabrese,Erica D. Dommasch,Steven R. Feldman,Dafna D. Gladman,Dafna D. Gladman,Leon H Kircik,Leon H Kircik,Mark Lebwohl,Vincent Lo Re,George R. Martin,Joseph F. Merola,Jose U. Scher,Sergio Schwartzman,James R. Treat,Abby S. Van Voorhees,Christoph T. Ellebrecht,Justine Fenner,Anthony Ocon,Maha N. Syed,Erica J. Weinstein,George Gondo,Sue Heydon,Samantha Koons,Christopher T. Ritchlin +28 more
TL;DR: The Task Force on Psoriasis during the COVID-19 pandemic as discussed by the authors included 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care to provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop CO